SCHEMBL654039

SCHEMBL654039

O=C1NC(=Nc2ccc3cn[nH]c3c2)S/C1=C\c1cnc(NCCCN2CCCC2)s1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.36
RAB9A P51151 4/20 0.36
HCRTR1 O43613 1/20 0.36
KMT2A Q03164 9/20 0.35
MEN1 O00255 8/20 0.35
LMNA P02545 2/20 0.35
POLB P06746 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
PSMD14 O00487 1/20 0.35
MAPK1 P28482 4/20 0.35
ALDH1A1 P00352 2/20 0.35
USP2 O75604 1/20 0.35
RECQL P46063 1/20 0.35
BLM P54132 1/20 0.35
SAE1 Q9UBE0 1/20 0.35
UBA2 Q9UBT2 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PKM P14618 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10227032 1.00 MAPT (0.36) MAPTRAB9AHCRTR1KMT2AMEN1
SCHEMBL654040 1.00 MAPT (0.36) MAPTRAB9AHCRTR1KMT2AMEN1
SCHEMBL10227930 0.93 MAPT (0.42) MAPTRAB9AHCRTR1KMT2AMEN1
SCHEMBL652003 0.93 MAPT (0.42) MAPTRAB9AHCRTR1KMT2AMEN1
SCHEMBL652004 0.93 MAPT (0.42) MAPTRAB9AHCRTR1KMT2AMEN1
SCHEMBL10227026 0.87 KMT2A (0.37) MAPTRAB9AHCRTR1KMT2AMEN1
SCHEMBL650789 0.87 KMT2A (0.37) MAPTRAB9AHCRTR1KMT2AMEN1
SCHEMBL650790 0.87 KMT2A (0.37) MAPTRAB9AHCRTR1KMT2AMEN1
SCHEMBL651347 0.86 KMT2A (0.37) MAPTRAB9AHCRTR1KMT2AMEN1
SCHEMBL10227917 0.86 KMT2A (0.37) MAPTRAB9AHCRTR1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 MAPT 3657/4885RAB9A 3157/4885HCRTR1 4349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.